
MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.
MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.
| Revenue (TTM) | $1.95B |
| Gross Profit (TTM) | $511.77M |
| EBITDA | $263.74M |
| Operating Margin | 13.40% |
| Return on Equity | 20.40% |
| Return on Assets | 7.11% |
| Revenue/Share (TTM) | $23.87 |
| Book Value | $11.11 |
| Price-to-Book | 2.38 |
| Price-to-Sales (TTM) | 1.10 |
| EV/Revenue | 1.188 |
| EV/EBITDA | 8.18 |
| Quarterly Earnings Growth (YoY) | 6.50% |
| Quarterly Revenue Growth (YoY) | 4.00% |
| Shares Outstanding | $81.25M |
| Float | $77.92M |
| % Insiders | 2.03% |
| % Institutions | 107.80% |
Volatility is currently expanding

MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

Pediatrix Medical Group NYSE: MD reported second-quarter 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million, as stronger revenue-cycle-management collections, payer mix and patient acuity offset lower patient-service volumes.

Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MD and any ticker you trade — then tracks every position and per-strategy win rate.